Northland Securities began coverage on shares of Isoray (NYSEAMERICAN:ISR) in a research report report published on Tuesday, The Fly reports. The brokerage issued an outperform rating and a $1.25 price objective on the healthcare company’s stock.
Separately, Zacks Investment Research raised Isoray from a sell rating to a hold rating in a research report on Thursday, July 15th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Isoray has a consensus rating of Buy and an average target price of $1.67.
Shares of NYSEAMERICAN:ISR opened at $0.72 on Tuesday. The company has a market cap of $101.57 million, a price-to-earnings ratio of -14.36 and a beta of 1.02. Isoray has a 12-month low of $0.35 and a 12-month high of $2.81. The stock’s fifty day moving average is $0.45.
Isoray Company Profile
IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
Read More: How to invest in blue-chip stocks
Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.